Your Good Partner in Biology Research

  1. 首页
  2. 试剂盒
  3. 酶联免疫试剂盒
  4. Human Receptor tyrosine-protein kinase erbB-3(ERBB3) ELISA kit

Human Receptor tyrosine-protein kinase erbB-3(ERBB3) ELISA kit

  • 中文名称：
    人受体酪氨酸蛋白激酶erbB-3(ERBB3)酶联免疫试剂盒
  • 货号：
    CSB-EL007765HU
  • 规格：
    96T/48T
  • 价格：
    ￥3600/￥2500
  • 其他：

产品详情

  • 别名：
    c erbB 3 ELISA Kit; c erbB3 ELISA Kit; Erb b2 receptor tyrosine kinase 3 ELISA Kit; ErbB 3 ELISA Kit; ERBB3 ELISA Kit; ERBB3 protein ELISA Kit; erbB3 S ELISA Kit; ERBB3_HUMAN ELISA Kit; Glial growth factor receptor ELISA Kit; HER 3 ELISA Kit; HER3 ELISA Kit; Human epidermal growth factor receptor 3 ELISA Kit; LCCS2 ELISA Kit; MDA BF 1 ELISA Kit; MGC88033 ELISA Kit; p180 ErbB3 ELISA Kit; p45 sErbB3 ELISA Kit; p85 sErbB3 ELISA Kit; proto-oncogene-like protein c ErbB 3 ELISA Kit; proto-oncogene-like protein c ErbB3 ELISA Kit; Proto-oncogene-like protein c-ErbB-3 ELISA Kit; Receptor tyrosine protein kinase erbB 3 ELISA Kit; Receptor tyrosine protein kinase erbB3 ELISA Kit; Receptor tyrosine-protein kinase erbB-3 ELISA Kit; Tyrosine kinase type cell surface receptor HER3 ELISA Kit; Tyrosine kinase-type cell surface receptor HER3 ELISA Kit; v erb b2 avian erythroblastic leukemia viral oncogene homolog 3 ELISA Kit; v erb b2 erythroblastic leukemia viral oncogene homolog 3 (avian) ELISA Kit; v erb b2 erythroblastic leukemia viral oncogene homolog 3 ELISA Kit
  • 缩写：
  • Uniprot No.：
  • 种属：
    Homo sapiens (Human)
  • 样本类型：
    serum, plasma, tissue homogenates
  • 检测范围：
    125 pg/mL-8000 pg/mL
  • 灵敏度：
    31.25 pg/mL
  • 反应时间：
    1-5h
  • 样本体积：
    50-100ul
  • 检测波长：
    450 nm
  • 研究领域：
    Signal Transduction
  • 测定原理：
    quantitative
  • 测定方法：
    Sandwich
  • 精密度：
    Intra-assay Precision (Precision within an assay): CV%<8%
    Three samples of known concentration were tested twenty times on one plate to assess.
    Inter-assay Precision (Precision between assays): CV%<10%
    Three samples of known concentration were tested in twenty assays to assess.
  • 线性度：
    To assess the linearity of the assay, samples were spiked with high concentrations of human ERBB3 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
    　 Sample Serum(n=4)
    1:1 Average % 87
    Range % 82-94
    1:2 Average % 98
    Range % 94-103
    1:4 Average % 102
    Range % 98-106
    1:8 Average % 95
    Range % 90-100
  • 回收率：
    The recovery of human ERBB3 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
    Sample Type Average % Recovery Range
    Serum (n=5) 92 88-97
    EDTA plasma (n=4) 103 96-110
  • 标准曲线：
    These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
    pg/ml OD1 OD2 Average Corrected
    8000 2.292 2.267 2.280 2.172
    4000 1.472 1.398 1.435 1.327
    2000 0.956 0.998 0.977 0.869
    1000 0.635 0.665 0.650 0.542
    500 0.364 0.352 0.358 0.250
    250 0.225 0.212 0.219 0.111
    125 0.171 0.181 0.176 0.068
    0 0.107 0.109 0.108 　
  • 数据处理：
  • 货期：
    3-5 working days

产品评价

靶点详情

  • 功能：
    Tyrosine-protein kinase that plays an essential role as cell surface receptor for neuregulins. Binds to neuregulin-1 (NRG1) and is activated by it; ligand-binding increases phosphorylation on tyrosine residues and promotes its association with the p85 subunit of phosphatidylinositol 3-kinase. May also be activated by CSPG5. Involved in the regulation of myeloid cell differentiation.
  • 基因功能参考文献：
    1. ERBB3 mutations can be found in a wide variety of tumour types, and can be used to select treatment with HER family inhibitors. PMID: 29413684
    2. identified P2RX2, KCNQ5, ERBB3 and SOCS3 to be associated with the progression of age-related hearing impairment PMID: 29325454
    3. Results demonstrate that 4-PBA promotes gastric cancer cells migration through upregulation of HER3/HER4 subsequent to increased levels of acetyl-histone and activation of ERK signaling. PMID: 28851073
    4. miR152 was found to be involved in the proliferation and metastasis of ovarian cancer cells through repression of ERBB3 expression. PMID: 29286064
    5. This phase Ib study was designed to determine the MTD, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) mAb SAR256212 in combination with the oral PI3K inhibitor SAR245408 for patients with metastatic or locally advanced solid tumors. PMID: 28031425
    6. To determine additional resistance mechanisms to cetuximab treatment besides HER3 signaling. PMID: 28910149
    7. Study shows ErbB3 expression was markedly decreased in suicide completers compared to controls. PMID: 28675388
    8. EGFR expression is increased in oesophageal and gastric adenocarcinomas after neoadjuvant therapy and was significantly associated with a prolonged overall survival in univariable analysis. PMID: 29138285
    9. Using time-resolved-fluorescence energy transfer (TR-FRET), we demonstrated that in the presence of recombinant NRG1, binding of 9F7-F11 to HER3 is increased, whereas that of ligand-competing anti-HER3 antibodies (H4B-121, U3-1287, Ab#6, Mab205.10.2, and MOR09825) is decreased. PMID: 28507002
    10. This study uncovers a direct relationship between HPV infection and HER3 in head and neck squamous cell carcinomas and provides a rationale for the clinical evaluation of targeted HER3 therapy for the treatment of HPV(+) patients. PMID: 27986750
    11. Cetuximab treatment induced HER3 activation and HER2/HER3 dimerization in head and neck squamous cell carcinoma cell lines. Cetuximab induces HER3 expression and activation in HNSCC cell lines. Upregulation of HER3 by cetuximab is one mechanism underlying resistance to EGFR inhibition in HNSCC. PMID: 27358485
    12. High HER3 expression is associated with breast cancer. PMID: 27582551
    13. hematopoietic expression of ERBB3 appears to be highest in bone marrow common myeloid and megakaryocyte-erythrocyte progenitors. Identified ERBB3 as a candidate gene for predisposition to erythroid MDS/AML PMID: 27416908
    14. High LINC00052 levels predict activation of HER3-mediated signaling, promoting breast cancer growth. PMID: 28036286
    15. we show that ErbB3 interacts with the ESCRT-0 subunit Hrs both in the presence and absence of heregulin. This indicates an ESCRT-mediated sorting of ErbB3 to late endosomes and lysosomes, and in line with this we show that impaired ESCRT function leads to an endosomal accumulation of ErbB3. PMID: 28867611
    16. our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression. PMID: 27447549
    17. Results indicate the feasibility by using a pharmacophore of the small molecular compound VS1 for designing and optimization of proto-oncogene protein erbB-3 (ERBB3) inhibitors. PMID: 27188722
    18. The A/A genotype of the ERBB3 rs2292239 SNP is associated with risk for T1DM in a white Brazilian population. PMID: 29109006
    19. Results shows that HER3 mRNA is upregulated in hepatocellular carcinoma associated to chronic HBV infection. PMID: 27514687
    20. Data show that afatinib resistant clones were selectively killed by knock down of ERBB3 + c-MET + c-KIT, but not by the individual or doublet knock down combinations, and the combination of afatinib with the SRC family inhibitor dasatinib killed afatinib resistant H1975 cells in a greater than additive fashion. PMID: 26934000
    21. results suggest that the combination of a histone deacetylase inhibitor (HDACi) plus an anti-ErbB3 MoAb represents a viable strategy that warrants further evaluation for the treatment of non-small cell lung cancer (NSCLC) patients. PMID: 26862736
    22. observations suggest that Rtn4A counteracts the Nrdp1-mediated degradation of ErbB3 by sequestering the ubiquitin ligase into ER tubules. PMID: 27353365
    23. Engineered multivalency enhanced affibody-mediated HER3 downregulation in multiple cancer cell types. PMID: 28248115
    24. Pretreatment with the soluble ErbB3 N418Q mutant suppressed heregulin beta1-induced HIF-1alpha activation in MCF7 cells. PMID: 25451255
    25. review and meta-analysis of essential role in clinicopathology and prognosis of gastric cancer PMID: 27536774
    26. HER3 is frequently overexpressed in high-grade dysplastic lesions of the gastroesophageal junction and may be a marker of invasive progression PMID: 27559738
    27. the mechanistic regulation and linkage of the ROR1-HER3 and Hippo-YAP pathway in a cancer-specific context PMID: 28114269
    28. Detecting nuclear ErbB380kDa could constitute a useful marker of prostate cancer progression. PMID: 27191720
    29. YAP induces the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2); YAP induces the expression of epidermal growth factor (EGF) receptors (EGFR, ERBB3) and production of EGF-like ligands (HBEGF, NRG1 and NRG2) PMID: 25798835
    30. In high-grade serous ovarian carcinoma (HGSC), high HER3 mRNA expression was a favorable prognostic factor for survival, while for high HER3 protein expression, a trend towards better survival was seen. A subgroup of HGSC with negative HER3 staining and negative HER3 mRNA levels showed most unfavorable survival. PMID: 27913862
    31. ERBB3 and ERBB4 have roles in lung adenocarcinoma PMID: 26254096
    32. Results suggest that silibinin is a potential anti-cancer drug to inhibit proliferative and invasive characteristics of the epithelial ovarian cancer (EOC) cells that exhibit an autocrine heregulin (HRG)/HER3 protein (HRG/HER3) pathway. PMID: 26482609
    33. findings suggest that HBx promotes the progression of hepatocellular carcinoma by decreasing the stability of Nrdp1, which results in up-regulation of ErbB3 PMID: 26846102
    34. High HER3 expression in colon cancer was associated to distal colon location and low-grade tumor. PMID: 26863446
    35. Correlate ERBB3 gene SNPs with rheumatoid arthritis susceptibility. PMID: 25530448
    36. Nrdp1S is a tumour suppressor that which potentiates the Nrdp1-mediated ubiquitination and degradation of ErbB3. An Nrdp1S deficiency may also be an important factor in the loss of Nrdp1. PMID: 26612725
    37. In response to trastuzumab, both HER3 and the metalloprotease ADAM10 are simultaneously upregulated. The proteolytic activity of the latter then releases the HER3 ligand heregulin from the cell surface to activate HER3 and confer resistance to trastuzumab by inducing compensatory growth factor receptor signaling. PMID: 26863569
    38. the identification of HER3-V855A and its functional properties for the first time clearly implicates genomic HER3 activation in the pathogenesis of lung cancer. PMID: 26689995
    39. These data indicate that erbB3 signaling is critical for both trastuzumab and lapatinib resistances mainly through the PI-3K/Akt pathway, whereas IGF-1R-initiated Src activation results in trastuzumab resistance without affecting lapatinib sensitivity. PMID: 26621843
    40. Data show that heat shock protein 90 (HSP90) inhibitor 17-DMAG caused loss of ret proto-oncogene protein (RET) and proto-oncogene protein erbB-3 (ERBB3) phosphorylation and lead to rapid cell death. PMID: 26595521
    41. Data indicate the role of proto-oncogene protein erbB-3 (ErbB3) in hepatitis B virus X protein (HBx)-mediated cell survival. PMID: 26595522
    42. our results suggest that HER3 over-expression may be associated with worse overall survival in gastric cancers PMID: 26517355
    43. Study shows that ERBB3 is a novel regulator of beta-cell apoptosis and found rs2292239 strongly correlated with residual b-cell function and metabolic control in children with type 1 diabetes. PMID: 26450151
    44. s show experimental evidence for an ErbB3 gain-of-function point mutation located in the C-lobe asymmetric dimerization interface, which shows enhanced phosphorylation at low ligand dose associated with increased kinase activity. PMID: 26378253
    45. HER2/HER3 interaction and increased expression was linked to risk for poor outcome in lung cancer patients. PMID: 26678909
    46. Data show that cotreatment with anti-ERBB3 proto-oncogene protein antibody seribantumab and letrozole had increased antitumor activity. PMID: 26310543
    47. HPV 16 E2 can modulate ErbB-3 by interacting with Nrdp-1, which is involved in the regulation of this receptor, via ubiquitination and degradation. PMID: 26963794
    48. findings show that the local 3D tumor microenvironment can trigger reprograming and switching of ErbB family members and thereby influence ErbB3-driven tumor growth PMID: 26073080
    49. ERa-dependent expression of LRIG1 dampens ErbB3 signaling in luminal breast cancer cells, and by blocking ERa activity with fulvestrant, LRIG1 is decreased thus permitting ErbB3 accumulation, enhanced ErbB3 signaling to cell survival pathways PMID: 26148232
    50. Data indicate that clathrin-mediated endocytosis of proto-oncogene protein erbB-3 (ErbB3) is depending on epsin-1. PMID: 26975582

    显示更多

    收起更多

  • 相关疾病：
    Lethal congenital contracture syndrome 2 (LCCS2)
  • 亚细胞定位：
    [Isoform 1]: Cell membrane; Single-pass type I membrane protein.; [Isoform 2]: Secreted.
  • 蛋白家族：
    Protein kinase superfamily, Tyr protein kinase family, EGF receptor subfamily
  • 组织特异性：
    Epithelial tissues and brain.
  • 数据库链接：

    HGNC: 3431

    OMIM: 190151

    KEGG: hsa:2065

    STRING: 9606.ENSP00000267101

    UniGene: Hs.118681